Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - ondansetron hydrochloride dihydrate, quantity: 10 mg (equivalent: ondansetron, qty 8 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - entecavir monohydrate, quantity: 0.532 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - entecavir-gh is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - entecavir monohydrate, quantity: 1.064 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - entecavir-gh is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; lauroyl macrogolglycerides; microcrystalline cellulose; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - apo-finasteride 5 is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; lauroyl macrogolglycerides; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - apo-finasteride 1 is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. apo-finasteride 1 is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 10 mg - tablet, film coated - excipient ingredients: maltodextrin; magnesium stearate; macrogol 6000; hydrophobic colloidal silica anhydrous; lactose monohydrate; sodium starch glycollate; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: maltodextrin; hydrophobic colloidal silica anhydrous; lactose monohydrate; macrogol 6000; sodium starch glycollate; magnesium stearate; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; sodium starch glycollate; macrogol 6000; hydrophobic colloidal silica anhydrous; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 35.12 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; croscarmellose sodium; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - sildenafil citrate, quantity: 140.48 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of erectile dysfunction in adult males. it is not indicated for use by women.